Vicore Pharma Holding ABOSTO:VICO +1.65%28 Quick Ratio is 12.69 as of Mar. 2026, which is 12% above its 10-year median of 11.36. GuruFocus rates OSTO:VICO with a GF Score™ of 28/100. The stock has 5 warning signs investors should review. Among 1,416 Biotechnology companies, Vicore Pharma Holding AB ranks better than 83.62% on this metric.
Vicore Pharma Holding AB has a quick ratio of 12.69. It generally indicates good short-term financial strength.
The historical rank and industry rank for Vicore Pharma Holding AB's Quick Ratio or its related term are showing as below:
OSTO:VICO'
s Quick Ratio Range Over the Past 10 Years
Min: 1 Med: 11.36 Max: 23.88
Current: 12.69
During the past 13 years, Vicore Pharma Holding AB's highest Quick Ratio was 23.88. The lowest was 1.00. And the median was 11.36.
OSTO:VICO's Quick Ratio is ranked better than 83.62% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs OSTO:VICO: 12.69
Vicore Pharma Holding AB (OSTO:VICO) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Vicore Pharma Holding AB Quick Ratio Related Terms
Vicore Pharma Holding AB Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:VICO vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Vicore Pharma Holding AB's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vicore Pharma Holding AB Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Vicore Pharma Holding AB's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Vicore Pharma Holding AB's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vicore Pharma Holding AB (OSTO:VICO) has a Quick Ratio of 12.69 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Vicore Pharma Holding AB and its competitors. This is 12% above median its historical median of 11.36. Over the past decade, Vicore Pharma Holding AB's Quick Ratio has ranged from 1.00 to 23.88. According to the industry distribution chart, Vicore Pharma Holding AB ranks #232 out of 1416 companies in the Biotechnology industry, placing it in the top 16.4%.
Is Vicore Pharma Holding AB's Quick Ratio too high?
Vicore Pharma Holding AB's current Quick Ratio of 12.69 is 12% above median its 10-year median of 11.36. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 23.88. The Biotechnology industry median Quick Ratio is 3.60. Vicore Pharma Holding AB's value of 12.69 is 252.5% above this industry median. Based on the distribution chart, Vicore Pharma Holding AB ranks #232 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vicore Pharma Holding AB has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Vicore Pharma Holding AB's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vicore Pharma Holding AB ranks #232 out of 1416 companies for Quick Ratio. This places Vicore Pharma Holding AB in the top 16% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Vicore Pharma Holding AB's value of 12.69 is 252.5% above this benchmark. Historically, Vicore Pharma Holding AB's own Quick Ratio has ranged from 1.00 to 23.88 over the past decade. While the company's 10-year median is 11.36 vs. the industry median of 3.60, Vicore Pharma Holding AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vicore Pharma Holding AB's current Quick Ratio of 12.69 is 252.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Vicore Pharma Holding AB and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vicore Pharma Holding AB's current Quick Ratio is 12.69, which is 12% above median its own 10-year median of 11.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vicore Pharma Holding AB stock overvalued right now?
Vicore Pharma Holding AB (OSTO:VICO) has a current Quick Ratio of 12.69. The current Quick Ratio is 12.69, which is 12% above median its 10-year median of 11.36 and 252.5% above the Biotechnology industry median of 3.60. Vicore Pharma Holding AB's overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Vicore Pharma Holding AB (OSTO:VICO), the current Quick Ratio is 12.69 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
28GF Score
Get the complete analysis for OSTO:VICO
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:VICO has been successfully added to your 
